0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > MIS RII

MIS RII

Brief Information

Name:Anti-Mullerian hormone receptor II
Target Synonym:Anti-Mullerian Hormone Receptor, Type II,AMHR2,MRII,AMH Type II Receptor,MISRII,Muellerian Inhibiting Substance Type II Receptor,MIS Type II Receptor,Anti-Muellerian hormone type-2 receptor,EC:2.7.11.30,Mullerian Inhibiting Substance Type II Receptor,MISR2,AMHR,Anti-Muellerian Hormone Type-2 Receptor,Anti-Mullerian Hormone Receptor Type 2,EC 2.7.11.30,Anti-Muellerian Hormone Type II Receptor,Anti-Mullerian Hormone Receptor Type II
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

ACRO Quality

Synonym Name

MIS RII,MRII,AMHR2,AMHR,MISR2,AMH type II receptor

Background

MIS RII (Mullerian inhibiting substance type II receptor), also known as AMHRII (anti-Mullerian hormone type II receptor), is a serine/threonine receptor with a single transmembrane domain that belongs to the family of type II receptors of the TGF-beta superfamily. Mutations in MIS RII result in persistent Mullerian duct syndrome (PMDS), persistent Müllerian duct syndrome (PMDS) is a sex-limited disorder in which males develop portions of the female reproductive tract. Anti-Müllerian hormone (AMH) and its receptor (AMHR2) induce the regression of the Müllerian ducts in male embryos, but the mechanism by which the Amhr2 gene is specifically activated is not fully understood.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Murlentamab 3C23-K; GM-102 Phase 2 Clinical Lfb Biotechnologies Sas Colorectal Neoplasms; Genital Neoplasms, Female Details
Murlentamab 3C23-K; GM-102 Phase 2 Clinical Lfb Biotechnologies Sas Colorectal Neoplasms; Genital Neoplasms, Female Details

This web search service is supported by Google Inc.

totop

Laisser un message